Filing Flows › Comparisons › IDYA vs NKTR
Ideaya Biosciences vs Nektar Therapeutics: IDYA and NKTR compared
Ideaya Biosciences is the larger company: $10.2M of revenue in its latest quarter (Q3 2026) against $10.1M for Nektar Therapeutics (Q2 2026). Nektar Therapeutics is growing faster (-9% against -95% a year earlier).
Where the money goes: IDYA and NKTR
Ideaya Biosciences (IDYA) · Q3 2026
Ideaya Biosciences, Q3 2026: revenue $10.2M (-95% year over year), net loss $126M, operating cash flow −$93.5M. The chart follows the revenue to costs, profit and cash.
Nektar Therapeutics (NKTR) · Q2 2026
Nektar Therapeutics, Q2 2026: revenue $10.1M (-9% year over year), operating margin -417.9%, net loss $40.6M, operating cash flow −$75.8M. The chart follows the revenue to costs, profit and cash.
| Ideaya Biosciences (IDYA) | Nektar Therapeutics (NKTR) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $10.2M | $10.1M |
| Revenue growth, Y/Y | -95% | -9% |
| Operating margin | n/m | -417.9% |
| Net earnings | −$126M | −$40.6M |
| Net margin | — | -401.0% |
| Operating cash flow | −$93.5M | −$75.8M |
| Market value | $3.7B | — |
| Analysts’ mean target | $51.38 | — |
Questions
Which is bigger, Ideaya Biosciences or Nektar Therapeutics?
Ideaya Biosciences is the larger company: $10.2M of revenue in its latest quarter (Q3 2026) against $10.1M for Nektar Therapeutics (Q2 2026).
Is Ideaya Biosciences or Nektar Therapeutics growing faster?
Nektar Therapeutics is growing faster (-9% against -95% a year earlier).
More: Ideaya Biosciences earnings · how Ideaya Biosciences makes money · Nektar Therapeutics earnings · how Nektar Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 3, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.